Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer

Published:2016-10 Issue:5 Volume:14 Page:389-397
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Colloca Giuseppe^ORCID,Vitucci Pasquale,Venturino Antonella^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference45 articles.

1. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5—a population-based study;De Angelis;Lancet Oncol,2014

2. Clinical states in prostate cancer: toward a dynamic model of disease progression;Scher;Urology,2000

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;De Bono;Lancet,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer;NEJM Evidence;2023-03-28

2. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study;Advances in Therapy;2022-04-10

3. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

4. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer;British Journal of Cancer;2020-09-11

5. Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis;European Journal of Clinical Pharmacology;2019-08-28